Vera Therapeutics (VERA) Stock Surges Following Promising ORIGIN3 Trial Results
TLDRShares of Vera Therapeutics increased 4% to $35.39 following the release of positive two-year ORIGIN3 trial results for TrutaknaThe kidney drug demonstrated the ability to slow kidney function decline to rates comparable with normal aging in IgA nephropathy patientsThe biotech company intends to submit a supplemental Biologics License Application during Q4 for full regulatory approvalTD Cowen maintained its Buy recommendation with a $78 price objective after reviewing the clinical dataDespite Tuesdays gain, VERA shares remain down 34% year-to-date amid competition from Vertex and Otsuka Vera Therapeutics experienced a 4% share price increase to $35.39 on Tuesday following the publication of two-year clinical data from the ORIGIN3 study evaluating Trutakna, providing a positive catalyst for a stock that has faced headwinds throughout 2026. Vera Therapeutics, Inc., VERA The clinical trial enrolled participants diagnosed with immunoglobulin A nephropathy, a progressive kidney disease characterized by abnormal IgA antibody deposits that impair the glomerulis filtration capacity. Study findings demonstrated that Trutakna reduced the pace of kidney deterioration to levels seen in normal physiological aging, representing a significant therapeutic achievement. Discover more Access Premium News Finance Compare Exchange Rates The annualized estimated glomerular filtration rate (eGFR) slope difference compared to placebo measured +5.0 mL/min/year. Treatment with Trutakna resulted in a two-year annualized eGFR









